Peer-Reviewed Publications

    Community-reviewed biological network models for toxicology and drug discovery applications

    Namasivayam, A. A.; Morales, A. F.; Lacave, Á. M. F.; Tallam, A.; Simovic, B.; Alfaro, D. G.; Bobbili, D. R.; Martin, F.; Androsova, G.; Shvydchenko, I.; Park, J.; Calvo, J. V.; Hoeng, J.; Peitsch, M. C.; Racero, M. G. V.; Biryukov, M.; Talikka, M.; Pérez, M. B.; Rohatgi, N.; Díaz-Díaz, N.; Mandarapu, R.; Ruiz, R. A.; Davidyan, S.; Narayanasamy, S.; Boué, S.; Guryanova, S.; Arbas, S. M.; Menon, S.; Xiang, Y.
    Published
    Jul 12, 2016
    DOI
    10.4137/grsb.s39076
    PMID
    27429547
    Link to publication
    Topic
    Summary

    Biological network models offer a framework for understanding disease by describing the relationships between the mechanisms involved in the regulation of biological processes. Crowdsourcing can efficiently gather feedback from a wide audience with varying expertise. In the Network Verification Challenge, scientists verified and enhanced a set of 46 biological networks relevant to lung and chronic obstructive pulmonary disease. The networks were built using Biological Expression Language and contain detailed information for each node and edge, including supporting evidence from the literature. Network scoring of public transcriptomics data inferred perturbation of a subset of mechanisms and networks that matched the measured outcomes. These results, based on a computable network approach, can be used to identify novel mechanisms activated in disease, quantitatively compare different treatments and time points, and allow for assessment of data with low signal. These networks are periodically verified by the crowd to maintain an up-to-date suite of networks for toxicology and drug discovery applications.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.